Company: PFSA
Filing Date: 2025-09-17
Form Type: S-1/A
Source: 0001213900-25-088333
Chunk: 157

Company: Profusa, Inc.
Filing Date: 2025-09-17
Form: S-1/A
Chunk 157
---
 expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post -vestingemployment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting -tranchefor awards with graded vesting. The mid -pointbetween the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting -tranches, the times from grant until the mid -pointsfor each of the tranches may be averaged to provide an overall expected term. • Expected Volatility. The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as we did not have any trading history for our common stock. We will continue to analyze the historical stock price volatility and expected term assumptions as historical data for our common stock becomes available. • Risk -Free Interest Rate. The risk -freeinterest rate is based on the implied yield currently available on the U.S. Treasury zero -couponissues with a remaining term equivalent to the expected term of a stock award. • Dividend Yield. We have not paid and does not anticipate paying any dividends in the near future. Accordingly, we have estimated the dividend yield to be zero. Recent Accounting Pronouncements See the section titled “Recent Accounting Pronouncements” in Note 2 of the notes to our unaudited condensed consolidated financial statements included in this Report for more information. 99 BUSINESS Overview Profusa is a digital health technology company based in Berkeley, CA, that has invested over the last twelve years more than $100 million from sophisticated venture investors as well as the most sophisticated research institutions in the U.S. (including approximately $30 million from Defense Advance Research Projects Agency, or DARPA, and the National Institutes of Health, of NIH) to develop a unique biosensor platform that is easily injected subcutaneously to provide, for the first time, real -time, individual biochemistry, that is cost effective while functioning for more than six times longer than known best in class solutions on the market today. Profusa’s Lumee™ technology does not consist of a single product, but is rather a platform that can potentially launch products for multiple applications. Profusa’s overall strategy has been to robustly invest and therefore develop and protect its technology as a private company, first in Europe where the barriers to regulatory approval traditionally are not as great as they are in the U.S. Accordingly, Profusa has validated its technology and